Samsung Biologics Publishes Prospectus for PolyPeptide Tender Offer

M&A · Partnership Impact 4
โดย PR Newswire·CHKR·Read original
Summary · why it matters

Samsung Biologics, through its Swiss subsidiary Samsung Peptide AG, has published the tender offer prospectus for all publicly held shares of PolyPeptide Group AG, offering CHF 44.31 net in cash per share, implying an aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40% premium over the unaffected share price on the SIX Swiss Exchange as of April 10, 2026, and an 11.6% premium over the volume-weighted average price of the last 60 trading days before the pre-announcement on July 20, 2026. PolyPeptide's board unanimously recommends acceptance, supported by a fairness opinion from IFBC AG, and Draupnir Holding B.V., holding about 55.65% of shares, has committed to tender all its shares. The main offer period runs from September 15 to October 12, 2026, subject to a minimum acceptance threshold of 66⅔% on a fully diluted basis and regulatory approvals. Following settlement, Samsung Peptide intends to pursue a squeeze-out of remaining minority shareholders and delist PolyPeptide from the SIX.

Impact on stocks 2

Biotech & Genomic Medicine▲ · 1 stocks
Samsung Biologics Co Ltd
207940
▲ PositiveCapitalrelevance

Samsung Biologics is acquiring PolyPeptide via its Swiss subsidiary at CHF 44.31/share, a ~CHF 1.46bn M&A deal.

Health Care▲ · 1 stocks
PolyPeptide Group AG
PPGN
▲ PositiveCapitalrelevance

PolyPeptide shareholders are offered CHF 44.31 net cash per share, a 40% premium, with board recommendation and delisting.

Theme Impact 1

Off-coverage companies 3

Samsung Peptide AGPrivate▲ Positive
Capitalrelevance

Samsung Peptide AG is the offeror making the tender offer for all PolyPeptide shares.

Draupnir HoldingPrivate± Mixed
relevance

Draupnir Holding, holding ~55.65%, committed to tender its shares; no independent impact on it.

IFBC AGPrivate± Mixed
relevance

Related news

Avantor Expands RIM Single-Use Bioprocessing Portfolio Across APAC

Avantor has expanded the availability of its RIM single-use bioprocessing portfolio across the Asia Pacific region, strengthening its presence in a key biopharma manufacturing market. The portfolio includes single-use consumables such as bioprocessing bags, assemblies, tubing and components, plus mixing and storage hardware, and is manufactured at Avantor's Changzhou, China facility, the company's first single-use production site in APAC. That 2,600-square-meter plant operates under ISO 9001:2015 certification and Good Manufacturing Practice standards, and RIM products are available exclusively to APAC customers. The move aligns with management's broader Revival strategy, and in the second quarter of 2026 the Bioscience & Medtech Products segment posted double-digit order growth and a book-to-bill ratio of 1.1x, with management expecting the segment to return to organic growth in the second half of 2026. Avantor currently has a market capitalization of $10.56 billion, and its shares have gained 38.4% year to date versus 3.4% growth for the industry and a 10.1% rise in the S&P 500.
AVTR ▲
Biotech & Genomic Medicine
Zacks Investment Research·15hRead more →
▲

Andelyn Begins Commercial Manufacturing of Ultragenyx's FDA-Approved FAYUVI Gene Therapy

Andelyn Biosciences announced it is now manufacturing FAYUVI, Ultragenyx Pharmaceutical Inc.'s FDA-approved gene therapy for Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, for commercial supply at its Columbus, Ohio facility. The move follows the U.S. Food and Drug Administration's approval of FAYUVI, making it the first FDA-approved gene therapy manufactured using the Andelyn AAV Curator Platform process. Sanfilippo syndrome type A is a rare, fatal lysosomal storage disease that primarily affects the central nervous system and is marked by rapid neurodegeneration beginning in early childhood; it is estimated to affect 3,000 to 5,000 patients worldwide, with a median life expectancy of 15 years. Andelyn Chief Executive Officer Wade Macedone said the company is proud to manufacture an FDA-approved gene therapy for commercial use using an AAV Curator Platform process, calling the milestone a reflection of the purpose behind Andelyn's founding. Andelyn, a full-service FDA-inspected cell and gene therapy commercial CDMO with more than 20 years of experience, has produced clinical and commercial material for more than 500 cGMP batches and 85 global clinical trials.
RARE ▲
Biotech & Genomic Medicine ▲
PR Newswire·17hRead more →
▲2

Charles River Laboratories Launches Rapid Cell Banking Platform With 40% Faster Production

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.
CRL
Biotech & Genomic Medicine ▲
Simply Wall St·20hRead more →
© 2026 MarketDXNews